Daniel M. Skovronsky, M.D., Ph.D. is Senior Vice President, Clinical and Product Development at Eli Lilly and Company, with responsibility for developing the Lilly pipeline of molecules and speeding innovative medicines to patients. Prior to this role he served as Vice President, Tailored Therapeutics. Dr. Skovronsky also serves as Chairman of Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly and Company).
Dr. Skovronsky joined Lilly in 2010 when the company acquired Avid Radiopharmaceuticals. Previously, Dr. Skovronsky served as CEO of Avid, which he founded in late 2004. At Avid, Skovronsky led the discovery, development, and FDA approval of Amyvid®, the first diagnostic agent for brain imaging of beta-amyloid plaques in patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive decline.
Dr. Skovronsky trained as a resident in pathology and completed a fellowship in neuropathology at the Hospital of the University of Pennsylvania. He received his M.D. and Ph.D. from the University of Pennsylvania and did his undergraduate training in molecular biophysics and biochemistry at Yale University.
Dr. Mark Mintun joined Avid Radiopharmaceuticals as Chief Medical Officer to lead clinical development programs for PET tracers for detecting and localizing tau deposits, beta-amyloid plaques, VMAT2 visualization, and other biomarker targets. Dr. Mintun added the title of President at Avid in 2014 and now oversees the implementation of the overall corporate strategy and leads the development process for all of Avidís imaging agents. Under Dr. Mintunís leadership, Avidís amyloid tracer has received marketing authorization in several countries and has now been implemented as a key imaging biomarker by Eli Lilly and other pharmaceutical companies for the development of beta-amyloid targeted therapeutics. More recently, Dr. Mintun has initiated a new clinical development program for tau imaging in evaluation of neurodegenerative diseases.
Dr. Mintun has been extensively involved in PET research for the past 35 years since he began investigating the nature of flow and metabolism changes in the human activated brain. He earned a B.S. in chemical engineering from the Massachusetts Institute of Technology, received his medical degree at Washington University School of Medicine, and completed a research fellowship in neurology and residency training in nuclear medicine. Prior to Avid, Dr. Mintun was Professor and Vice-Chair of radiology at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine, with joint appointments in the Psychiatry, Neurology, Bioengineering, and Anatomy and Neurobiology Departments. In addition to his own NIH-funded research projects on brain metabolism, he was Director of the Center for Clinical Imaging Research, Principal Investigator of the NINDS Center Core for Brain Imaging, and Director of the Neuroimaging Core of the Human Aging and Senile Dementia Program Project with Washington University's Alzheimerís Disease Research Center.
Over the past 25 years, Dr. Attardo has headed the discovery of numerous therapeutic and diagnostic preclinical drug candidates and progressed over a dozen compounds to CNS and oncology human clinical trials. Since joining Avid in 2011, Dr. Attardo has helped expand the discovery team and currently leads discovery research and preclinical development. Dr. Attardoís team has delivered several new radiopharmaceutical tracers for exploratory clinical trials, and he has led the non-clinical development of a new tau imaging agent.
Dr. Attardo received his doctorate from McGill University and completed industrial postdoctoral research at BioChem Pharma, focused on the design and synthesis of novel oncolytics. He has also worked on the synthesis of racemic 3TCTM, an antiviral agent currently used in the treatment of HIV and Hepatitis B. Before joining Avid, Dr. Attardo held positions of increasing responsibility to the appointment of Senior Director at both Chlorion Pharma and Gemin X Pharmaceuticals. His R&D effort at Gemin X provided two oncology drug candidates, Obatoclax and Teglarinad, which were pivotal assets in the acquisition of Gemin X by Cephalon. Prior to Gemin X, Dr. Attardo was Associate Director of Chemistry at BioChem Pharma and Shire Pharmaceuticals. Dr. Attardo is an inventor on more than 60 patents and patent applications and has co-authored over 40 publications and 75 conference presentations.
Dr. Benedum began working at Avid Radiopharmaceuticals in 2005. During his 10 years at Avid, Dr. Benedum has played a key role in advancing Avidís amyloid tracer through Proof-of-Mechanism studies, CMC development, FDA and EMA approval, and commercialization. Dr. Benedum received his Ph.D. in organic chemistry from the University of Virginia and did his undergraduate training in chemistry at Washington College. Prior to joining Avid, Dr. Benedum completed a fellowship at the University of Pittsburgh where he trained in natural product synthesis focused on a class of promising anti-proliferative, anti-cancer agents.
Dr. Devous joined Avid in 2013 after previous serving as an early scientific advisor. His research has focused on advancing our understanding of the pathobiology of neurologic and psychiatric disorders, as well as understanding normal brain function, through cutting-edge molecular, functional, and structural neuroimaging techniques, including PET, SPECT, and various MRI techniques (fMRI, rCBF/ASL, functional (fcMRI) and structural (DTI) connectivity, and morphometrics). At Avid Dr. Devous is responsible for providing strategic input toward Avidís corporate goals, supervising the development of analytic techniques for image analyses, correlating image data with other biomarkers, as well as cognitive and clinical measures in clinical and research trials, collaborating with academic and industry partners, and developing and supervising reader training activities.
Prior to joining Avid, Dr. Devous served for more than 30 years as a professor of radiology, neurology, radiological sciences and bioengineering at the University of Texas Southwestern Medical Center, Dallas, Texas where he was Principal or Co-Investigator on several NIH grants, as well as numerous industry collaborations. He was Director of Neuroimaging for the Alzheimer's Disease Center and Co-PI of the North Texas Traumatic Brain Injury Model System. He remains an adjunct professor of neurology at UT Southwestern as well as of Behavioral and Brain Sciences at the University of Texas at Dallas. He has authored more than 150 peer-reviewed articles, 300 abstracts, and 30 books or book chapters and has served as an editorial board member or consultant on more than a dozen journals. Dr. Devous is past president of the Society of Nuclear Medicine, the Education and Research Foundation, and the Brain Imaging Council. He was a member of the Board of Directors of the Academy of Radiology Research, and is a former chair of the Medical Imaging Drugs Advisory Committee for the Food and Drug Administration.
Michael Krautkramer joined Avid with over 10 years of experience in the medical device and diagnostics industry. Since joining Avid, Michael has operationally supported several aspects of imaging agent development including the submission of the florbetapir NDA and the development of the reader training program. Today, Mr. Krautkramer leads Avidís operations team and is responsible for supporting internal tracer development as well as leading the interface between Avidís late-stage diagnostic tools and Lillyís therapeutic development programs.
Mr. Krautkramer received his B.S. in Mechanical Engineering from the University of Wisconsin-Madison and an M.B.A. in Finance and Healthcare Management from the Wharton School at the University of Pennsylvania. In his previous roles at Guidant/Boston Scientific, Mr. Krautkramer held various positions of increasing responsibility in quality, manufacturing, R&D and product sales, all focused on delivering innovative life-saving medical technology to healthcare providers. Prior to joining Avid, he spent time as an Associate at the venture capital firm Safeguard Scientifics with a primary focus on evaluating potential investments in early stage diagnostics, specializing in pharmaceutical and medical device companies.
Dr. Lister-James has over 25 years of experience in research and development in the pharmaceutical industry, principally in the area of radiopharmaceuticals. Dr. Lister-James has directed CMC development leading to the regulatory approval of three diagnostic radiopharmaceutical products and played a key role in the R&D activities leading to the discovery and early development of multiple radiodiagnostic and radiotherapeutic products. At Avid, Dr. Lister-James leads the effort to develop Avidís global best-in-class Amyloid-PET manufacturing and distribution network, which includes over 50 production sites in the US, Canada, Europe, Japan, South America, and Australia. Dr. Lister-James is also responsible for several patents related to PET radiosynthesis and leads efforts to improve production yields to support the growing demand for Avidís radiopharmaceutical products.
Dr. Lister-James received his Ph.D. in organic chemistry from the University of London and completed his post-doctoral work at MIT and Harvard Medical School on the chemistry of technetium and its application in medical imaging. Dr. List-James previously held management and senior management positions at Centocor, Diatide, Berlex/Schering AG, CIS-US and Xanthus. Prior to joining Avid, Dr. Lister-James held the position of Vice President, Development at Xanthus Pharmaceuticals, a specialty company, and he was previously responsible for Corporate CMC Development, Radiopharmaceuticals in Schering AG. He is a co-inventor of 60 U.S. patents and has co-authored over 35 peer-reviewed articles.
Dr. Pontecorvo brings to Avid more than 25 years of pharmaceutical industry experience in both CNS discovery research and clinical development. Since joining Avid, Dr. Pontecorvo has been instrumental in the early development of Avidís amyloid tracer, leading the effort to select the best compound for development and culminating in a successful NDA. Dr. Pontecorvoís ongoing work focuses on imaging and clinical development of imaging agents for neurodegenerative disorders, with a focus on Alzheimerís disease dementia.
Dr. Pontecorvo graduated from Indiana University with a Ph.D. in psychology and neuroscience. Dr. Pontecorvo has held positions of increasingly responsibility in clinical development as a project leader at Janssen Pharmaceutica and as Vice President for Clinical Research at Mitsubishi Pharma America and Dov Pharmaceuticals. Dr. Pontecorvo has a long history working in Alzheimer's disease research and led the U.S. development of the Alzheimer's disease medication galantamine. Dr. Pontecorvo is the author of more than 70 publications, numerous invited presentations, and six patents.